हमारा समूह 1000 से अधिक वैज्ञानिक सोसायटी के सहयोग से हर साल संयुक्त राज्य अमेरिका, यूरोप और एशिया में 3000+ वैश्विक सम्मेलन श्रृंखला कार्यक्रम आयोजित करता है और 700+ ओपन एक्सेस जर्नल प्रकाशित करता है जिसमें 50000 से अधिक प्रतिष्ठित व्यक्तित्व, प्रतिष्ठित वैज्ञानिक संपादकीय बोर्ड के सदस्यों के रूप में शामिल होते हैं।
ओपन एक्सेस जर्नल्स को अधिक पाठक और उद्धरण मिल रहे हैं
700 जर्नल और 15,000,000 पाठक प्रत्येक जर्नल को 25,000+ पाठक मिल रहे हैं
Sahar Dadkhahfar, Mozhdeh Gheisari, Zahra Mahboubi-Fooladi*and Mohammad Shahidi Dadras
Background and Objective: Psoriasis is a systemic autoimmune disease that is associated with numerous comorbidities. This study aimed to compare the prevalence of Small Vessel Cerebrovascular Disease (SVCD) and atrophic brain changes in MRI of patients with psoriasis and normal subjects.
Materials and Methods: This case control study was performed on 27 patients with psoriasis and 27 normal individuals who were referred to Shohada-e-Tajrish hospital, Tehran, Iran during 2019 and 2020. Basic demographic and clinical information of participants were recorded. Brain MRI was performed for all individuals to examine the Medial Temporal Atrophy (MTA) score, Global Cortical Atrophy (GCA) score, and Fazekas scale. Finally, the relative frequencies of each parameter between the two groups were compared.
Results: There was no significant difference in the frequency of the Fazekas scale, GCA, and MTA scores between the two groups. However, a mild trend was found for higher frequency of Fazekas scale, GCA, and MTA scores in controls in comparison with the case group. While there was no significant relationship between the Fazekas scale and disease duration (p=0.16), a significant and positive correlation was found between disease duration and GCA and MTA scores (p<0.001). There was no significant relationship between Fazekas, GCA and MTA status and other parameters.
Conclusion: The increase in disease duration was significantly associated with increase in the incidence of cerebral atrophy, which may suggest the need for screening in terms of CNS involvement in psoriasis patients.